Last quarter (Q3 2023), eFFECTOR Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q3, eFFECTOR Therapeutics's net income was $-8.30M. See eFFECTOR Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20
Total Revenue	$ 675.00K	$ 3.55M	$ 1.43M	$ 42.00M
Cost of Revenue	-	-	-	-
Gross Profit	$ 675.00K	$ 3.55M	$ 1.43M	-
Operating Expense	$ 15.85M	$ 35.96M	$ -33.33M	$ 26.18M
Operating Income	$ -33.97M	$ -32.40M	$ -31.90M	$ 15.82M
Net Non Operating Interest Income Expense	$ -1.90M	$ -1.81M	$ 47.15M	$ -1.27M
Other Income Expense	$ 72.00K	$ -11.55M	$ -543.00K	$ 9.00K
Pretax Income	$ -35.94M	$ -22.66M	$ 15.80M	$ 14.56M
Tax Provision	$ -62.00M	$ -2.08M	-	$ 351.00K
Earnings From Equity Interest Net Of Tax	-	-	-	-
Net Income Common Stockholders	$ -35.94M	$ -22.66M	$ 15.80M	$ 166.00K
Basic EPS	$ -0.77	$ -0.55	$ 1.05	$ <0.01
Diluted EPS	$ -0.76	$ -0.55	$ 0.44	$ <0.01
Basic Average Shares	$ 192.78M	$ 41.18M	$ 15.11M	$ 40.67M
Diluted Average Shares	$ 192.78M	$ 41.18M	$ 36.00M	$ 40.67M
Dividend Per Share	-	-	-	-
Total Operating Income As Reported	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-
Rent Expense Supplemental	-	-	-	-
Total Expenses	$ 15.85M	$ 35.96M	$ -33.33M	$ 26.18M
Net Income From Continuing And Discontinued Operation	$ -35.94M	$ -22.66M	$ 15.80M	$ 14.21M
Normalized Income	$ -6.61M	$ -24.73M	-	$ 14.21M
Interest Expense	-	-	-	$ 1.33M
EBIT	$ -33.52M	$ -20.41M	$ -31.35M	$ 15.89M
EBITDA	$ -78.87M	$ -20.36M	$ -31.38M	$ 16.05M

Currency in USD

eFFECTOR Therapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing